Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Southern Medical University, China
ClinicalTrials.gov Identifier:
NCT01171235
First received: July 27, 2010
Last updated: NA
Last verified: March 2009
History: No changes posted
  Purpose

The aim of the study is to find for one or more serum or tissue markers of molecular biology in head and neck cancer patients used for early diagnosis, predicting prognosis and being sensitive to chemotherapy and radiotherapy


Condition
Laryngeal Neoplasms
Pharyngeal Neoplasms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma

Resource links provided by NLM:


Further study details as provided by Southern Medical University, China:

Biospecimen Retention:   Samples With DNA

blood and tissue samples


Estimated Enrollment: 200
Study Start Date: July 2010
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Detailed Description:

Head and neck malignant tumors, especially nasopharyngeal carcinoma in southern China with the high incidence, its incidence, treatment, prognosis or tumor markers in serum has been a hot research with little progress.In our study, we collect NPC-based collection including the blood samples of laryngeal, hypopharyngeal cancer, separating serum and white blood cells stored in -80 degrees,while tissues are frozen in liquid nitrogen and embedded in paraffin。 Patient treatment and prognosis are combined in order to find for markers of molecular biology used for early diagnosis, predicting prognosis and being sensitive to chemotherapy and radiotherapy.

  Eligibility

Ages Eligible for Study:   15 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

all of nasopharyngeal carcinoma, hypopharyngeal carcinoma or laryngeal carcinoma visited at ENT department of NanFang hospital

Criteria

Inclusion Criteria:

  • all of nasopharyngeal carcinoma
  • hypopharyngeal carcinoma or laryngeal carcinoma visited at ENT department of NanFang hospital

Exclusion Criteria:

  • all of above patients whose anticipated survival duration were less than 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01171235

Sponsors and Collaborators
Southern Medical University, China
Investigators
Study Director: Ping Xiang Li, doctor E.N.T department of NanFang hospital
  More Information

No publications provided

Responsible Party: E.N.T department of Nan Fang Hospital, Nan Fang Medical University, China: National Natural Science Foundation
ClinicalTrials.gov Identifier: NCT01171235     History of Changes
Other Study ID Numbers: NFYY-H&N-1
Study First Received: July 27, 2010
Last Updated: July 27, 2010
Health Authority: China: National Natural Science Foundation

Keywords provided by Southern Medical University, China:
Laryngeal Neoplasms
Pharyngeal Neoplasms

Additional relevant MeSH terms:
Neoplasms
Carcinoma
Laryngeal Neoplasms
Pharyngeal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Laryngeal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Otorhinolaryngologic Diseases
Pharyngeal Diseases
Stomatognathic Diseases

ClinicalTrials.gov processed this record on September 18, 2014